Insulin metformin
Searched over 200M research papers for "insulin metformin"
Summary
10 papers analyzed
These studies suggest that metformin is effective in improving diabetes-related outcomes, glycemic control in gestational diabetes, insulin sensitivity, and certain reproductive health issues in women with PCOS, while its long-term cardiovascular benefits and impact on live birth rates remain unclear.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Comparative Analysis of Insulin and Metformin in Diabetes and Related Conditions
Metformin Monotherapy for Type 2 Diabetes
Glycemic Control and Weight Management
Metformin is widely recognized for its efficacy in managing type 2 diabetes mellitus, particularly in overweight or obese patients. Studies have shown that metformin monotherapy significantly improves glycemic control, reduces body weight, and lowers lipid levels compared to other treatments such as sulphonylureas, thiazolidinediones, and insulin. Additionally, metformin has been associated with a reduction in diastolic blood pressure and insulinaemia, making it a comprehensive option for managing type 2 diabetes.
Mortality and Vascular Complications
Metformin has demonstrated a significant benefit in reducing all-cause mortality and diabetes-related complications, including myocardial infarction, when compared to other treatments. This makes it a preferred first-line therapy for type 2 diabetes, especially in patients with obesity.
Metformin vs. Insulin in Gestational Diabetes
Glycemic Control and Maternal Outcomes
In gestational diabetes mellitus (GDM), metformin has been shown to achieve comparable glycemic control to insulin, with some studies indicating better postprandial glycemia after meals. Metformin treatment is also associated with fewer hypoglycemic episodes and less maternal weight gain compared to insulin . Additionally, metformin-treated women have lower rates of labor induction and cesarean deliveries.
Perinatal Outcomes
Perinatal outcomes such as birth weight, macrosomia, and large-for-gestational-age infants are similar between metformin and insulin treatments, suggesting that metformin is a safe and effective alternative to insulin in managing GDM .
Metformin in Polycystic Ovary Syndrome (PCOS)
Reproductive and Metabolic Benefits
Metformin has been found to improve clinical pregnancy rates and ovulation rates in women with PCOS, although it does not significantly impact live birth rates . The drug reduces hyperinsulinemia and hyperandrogenemia, leading to improved menstrual regularity and ovulation in a significant number of women. Long-term use of metformin also shows sustained improvements in menstrual abnormalities and resumption of ovulation.
Predictors of Response
Baseline characteristics such as higher plasma insulin, lower serum androstenedione, and less severe menstrual abnormalities are predictors of a positive clinical response to metformin in women with PCOS.
Metformin in Type 1 Diabetes
Insulin Sensitivity and Cardiovascular Risk
In adolescents with type 1 diabetes, metformin has been shown to improve whole-body and peripheral insulin sensitivity, although it does not significantly impact hepatic insulin sensitivity. In adults with type 1 diabetes, metformin reduces body weight, LDL cholesterol, and HbA1c levels, although these benefits are not sustained long-term. The drug also shows potential in reducing the progression of atherosclerosis, as indicated by a reduction in maximal carotid intima-media thickness.
Metformin in Alzheimer's Disease
Cognitive and Biomarker Improvements
Preliminary studies suggest that metformin may improve executive functioning and show trends towards better learning and memory in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. These findings warrant further investigation to confirm the potential cognitive benefits of metformin in Alzheimer's disease.
Conclusion
Metformin is a versatile medication with proven benefits in managing type 2 diabetes, gestational diabetes, and PCOS. It offers comparable glycemic control to insulin in GDM and improves reproductive outcomes in PCOS. In type 1 diabetes, metformin enhances insulin sensitivity and may reduce cardiovascular risk. Emerging evidence also suggests potential cognitive benefits in Alzheimer's disease. Overall, metformin remains a cornerstone in the management of various metabolic and endocrine disorders.
Sources and full results
Most relevant research papers on this topic
